The dispensing and drug accountability responsibilities of investigational agents are critical to the research process. The number and complexity of investigator-initiated studies was the driving force behind the creation of the Investigational Drug Service (IDS) by the Department of Pharmacy and Clinical Research Services. IDS provides expert pharmaceutical consultation for each pilot, phase I and II investigator-initiated research study, utilizing pharmaceutical products. Barbara Todaro, PharmD, is the IDS Director;in 2006, she consulted on thirty-one investigator-initiated studies prior to SRC submission. Alison Meagher, PharmD, is the assistant director of the Phase I committee. Under Dr. Meagher's direction the reporting processes for adverse events and monitoring of phase I patients has been streamlined. At the time of this submission, IDS was responsible for 72 inventory items for 43 separate investigatorinitiated studies. A member of IDS attends all study initiation meetings and in 2006, there were 15 implementation meetings for investigator-initiated research studies. IDS works closely with RPCI investigators to ensure appropriate drug and dosage forms are available for investigational drugs requiring complex preparation procedures. Examples include studies involving intravenous calcitriol, bupropion and tetrathiomolybdate, which are supported by multiple grants in several CCSG programs. 3.3 FTEs are required to support all relevant clinical trials that are under the RPCI protocol-specific research support. This application seeks 0.3FTE support for this function, with additional support to be provided by institutional sources as well as study sponsors (NIH/CTEP, industry, foundations). $33,281 in CCSG support is requested.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-36
Application #
8375984
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
36
Fiscal Year
2012
Total Cost
$70,209
Indirect Cost
$27,793
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :
Zhang, Dingxiao; Tang, Dean G; Rycaj, Kiera (2018) Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol 52:94-106
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Leonova, Katerina; Safina, Alfiya; Nesher, Elimelech et al. (2018) TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. Elife 7:

Showing the most recent 10 out of 1555 publications